New method described for quantifying antisense oligonucleotides in nuclei

November 14, 2019

New Rochelle, NY, November 14, 2019--A novel method uses subcellular fractionation to quantify label-free antisense oligonucleotides (AONs)- designed to silence targeted genes - that have crossed into the nucleus of a cell, where they can exert their effects. Researchers used this method to correlate nuclear entry of several AON molecules with target gene knockdown and they report their results in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers. Click here to read the full-text open access article for free on the Nucleic Acid Therapeutics website.

Troels Koch and colleagues from Roche Innovation Center Copenhagen, Hørsholm, Denmark coauthored the article entitled "Nuclear and Cytoplasmatic Quantification of Unconjugated, Label-Free Locked Nucleic Acid Oligonucleotides." Their method combines three main techniques: subcellular fractionation; nucleus counting; and Locked Nucleic Acid (LNA) sandwich Enzyme-Linked Immunosorbent Assay (ELISA) to determine the absolute numbers of AONs in nuclei. These unconjugated LNA oligonucleotides lack any labels that could alter their distribution in the cell. The researchers showed that increased nuclear entry was proportional to increased target gene knockdown, but depending on the compound and the target, other factors could impact the target transcript level reduction.

"As we anticipate the increase in oligonucleotide-based therapeutics, we must acknowledge it is one thing to know how many oligonucleotides are administered to the patient, it is quite another to know how many accumulate in the target cell nuclear fraction," says Executive Editor Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI.
-end-
About the Journal

Nucleic Acid Therapeutics is an authoritative peer-reviewed journal published bimonthly in print and online that focuses on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. The Journal is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center and Annemieke Aartsma-Rus, PhD, Leiden University Medical Center, and Executive Editor Graham C. Parker, PhD. Nucleic Acid Therapeutics is the official journal of the Oligonucleotide Therapeutics Society. Complete tables of content and a sample issue may be viewed on the Nucleic Acid Therapeutics website.

About the Society

The Oligonucleotide Therapeutics Society is an open, non-profit forum to foster academia- and industry-based research and development of oligonucleotide therapeutics. The society brings together the expertise from different angles of oligonucleotide research to create synergies and to bring the field of oligonucleotides to its full therapeutic potential.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Human Gene Therapy, Assay and Drug Development Technologies, Applied In Vitro Toxicology, and DNA and Cell Biology. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Mary Ann Liebert, Inc./Genetic Engineering News

Related Nuclear Articles from Brightsurf:

Explosive nuclear astrophysics
An international team has made a key discovery related to 'presolar grains' found in some meteorites.

Nuclear medicine and COVID-19: New content from The Journal of Nuclear Medicine
In one of five new COVID-19-related articles and commentaries published in the June issue of The Journal of Nuclear Medicine, Johnese Spisso discusses how the UCLA Hospital System has dealt with the pandemic.

Going nuclear on the moon and Mars
It might sound like science fiction, but scientists are preparing to build colonies on the moon and, eventually, Mars.

Unused stockpiles of nuclear waste could be more useful than we might think
Chemists have found a new use for the waste product of nuclear power -- transforming an unused stockpile into a versatile compound which could be used to create valuable commodity chemicals as well as new energy sources.

Six degrees of nuclear separation
For the first time, Argonne scientists have printed 3D parts that pave the way to recycling up to 97 percent of the waste produced by nuclear reactors.

How to dismantle a nuclear bomb
MIT team successfully tests a new method for verification of weapons reduction.

Material for nuclear reactors to become harder
Scientists from NUST MISIS developed a unique composite material that can be used in harsh temperature conditions, such as those in nuclear reactors.

Nuclear physics -- probing a nuclear clock transition
Physicists have measured the energy associated with the decay of a metastable state of the thorium-229 nucleus.

Milestones on the way to the nuclear clock
For decades, people have been searching for suitable atomic nuclei for building an ultra-precise nuclear clock.

Nuclear winter would threaten nearly everyone on Earth
If the United States and Russia waged an all-out nuclear war, much of the land in the Northern Hemisphere would be below freezing in the summertime, with the growing season slashed by nearly 90 percent in some areas, according to a Rutgers-led study.

Read More: Nuclear News and Nuclear Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.